)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Virbac
Virbac (VIRP) investor relations material
Virbac Q3 2026 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 TU earnings summary19 Oct, 2026
Executive summary
YTD September revenue reached €1,168m, up 7.9% at constant exchange rates and scope (CERS); Q3 revenue was €400m, up 8.8% CERS.
Growth was balanced across Companion Animal and Farm Animal, supported by Supercharge platforms and positive performance across all three regions.
Financial highlights
YTD September revenue increased 5.9% at actual rates, versus 7.9% CERS, reflecting currency headwinds.
Q3 revenue rose 9.8% at actual rates and 8.8% CERS; Q1 and Q2 CERS growth was 7.7% and 7.2%, respectively.
YTD growth included a 1.3 percentage-point contribution from the Thyronorm acquisition; Supercharge platforms excluding Thyronorm grew around 11% CERS.
YTD volume/mix contributed ~6% and price increases ~2%.
Outlook and guidance
FY2026 revenue growth guidance remains 5.5%–7.5% at constant rates and scope; strong nine-month performance supports targeting the upper end.
Adjusted recurring operating income margin is expected around 17% CERS; Thyronorm is expected to contribute ~0.5 percentage points to adjusted EBIT for the full year.
Thyronorm is included in the 2026 organic perimeter due to its low materiality; its full-year revenue contribution is expected to be ~1 percentage point of growth.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Virbac
- Nine-month revenue up 12.6% to €1,042.1M, led by companion animal growth and acquisitions.VIRP
Q3 2024 TU - 7.4% revenue growth and 18.8% EBIT margin in H1 2026, guidance at upper end.VIRPH1 2026
- H1 2026 revenue rose 7.4% at CERS, with strong growth across all segments and regions.VIRPQ2 2026 TU
- Q1 2026 revenue rose 7.7% at CERS, driven by double-digit North America and Supercharge growth.VIRPQ1 2026 TU
- 7.9% organic revenue growth, 16.3% EBIT margin, and strong cash flow drive 2026 outlook.VIRPH2 2025
- 2025 revenue rose 7.9% at constant rates, with 2026 growth and margin outlook boosted by acquisitions.VIRPQ4 2025 TU
- Revenue up 5.0% to €738.3M; margin down; 2025 outlook and guidance reaffirmed.VIRPH1 2025
- H1 2024 revenue up 15.1% and net income up 26.9%, driven by organic growth and acquisitions.VIRPH1 2024
- 13.6% revenue growth, record profit, and strong margin expansion in 2024.VIRPH2 2024
Next Virbac earnings date
Q4 2026 TU19 Jan, 2027
Virbac
Next Virbac earnings date
Q4 2026 TU19 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
French Animal Health
Virbac is a French veterinary pharmaceutical company with multinational operations. The company focuses on developing, producing, and marketing a wide range of drugs and vaccines to improve the health and well-being of pets and livestock. Their product portfolio covers various areas, including parasitology, dermatology, dental care, antibiotics, and nutrition for animals. It is headquartered in Carros, France, and its shares are traded on the XPAR.
From a Small Clinic to a Global Giant
What would go on to become a global company and one of the largest companies in worldwide animal health was started as a veterinary office in a mall in Nice, France. Its founders, veterinarians Pierre-Richard Dick and Max Rombi sold the office after a few years and started to focus solely on medications and drugs for pets. This is something that helped Virbac establish itself, as most other similar companies at the time focused on livestock. During the 1970s, the company expanded by opening subsidiaries in several countries, and Virbac of today is a truly global company. Today, the company produces products and medications for both companion animals and livestock, and a large majority of its revenue is generated outside of France. Some other large companies operating in the sector include Zoetis and Elanco.
Pet Health
Their portfolio includes a variety of pharmaceuticals, vaccines, and nutritional supplements designed for both dogs and cats. Key product categories encompass flea and tick control, dental care, dermatology, and kidney health, along with a broad spectrum of vaccines to prevent common infectious diseases. Additionally, Virbac provides nutritional supplements that support overall pet wellness, aimed at reducing issues like joint health and digestion.
Products for Livestock
Virbac's product range in the livestock sector encompasses a comprehensive array of health solutions, targeting cattle, sheep, pigs, and poultry. Their portfolio includes vaccines and parasiticides, essential in controlling internal and external parasites that can affect animal health and productivity. Virbac also produces products for reproductive health and nutrition.